Drug firm in partnership with BioNTech to seek US approval after trials found vaccine ‘well-tolerated’ in school-age children
Pfizer plans to seek emergency approval for its Covid vaccine in younger people after a US trial found the jab prevented the disease and was “well-tolerated” in 12- to 15-year-olds.
Related: Germany restricts use of AstraZeneca jab to over-60s
